MENU
+Compare
DNTH
Stock ticker: NASDAQ
AS OF
Apr 2, 04:59 PM (EDT)
Price
$17.79
Change
+$0.96 (+5.70%)
Capitalization
573.76M

DNTH Dianthus Therapeutics Forecast, Technical & Fundamental Analysis

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies... Show more

DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for DNTH with price predictions
Apr 01, 2025

DNTH in upward trend: price may ascend as a result of having broken its lower Bollinger Band on April 01, 2025

DNTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 34 cases where DNTH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for DNTH's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DNTH advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 19, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on DNTH as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for DNTH turned negative on March 14, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

DNTH moved below its 50-day moving average on March 12, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for DNTH crossed bearishly below the 50-day moving average on March 19, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNTH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for DNTH entered a downward trend on March 28, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.628) is normal, around the industry mean (13.458). P/E Ratio (3.238) is within average values for comparable stocks, (64.587). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.867). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (95.238) is also within normal values, averaging (251.391).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNTH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. DNTH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

DNTH is expected to report earnings to fall 19.58% to -303 cents per share on September 18

Dianthus Therapeutics DNTH Stock Earnings Reports
Q2'23
Est.
$-3.04
Q3'23
Missed
by $3.22
Q1'23
Missed
by $0.07
Q4'22
Missed
by $0.02
Q3'22
Beat
by $0.02
The last earnings report on November 09 showed earnings per share of -377 cents, missing the estimate of -56 cents. With 949.11K shares outstanding, the current market capitalization sits at 573.76M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
7 Times Square
Phone
+1 929 999-4055
Employees
53
Web
https://www.dianthustx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSDAX19.58N/A
N/A
Fidelity Select Defense & Aerospace
SVALX6.30N/A
N/A
Federated Hermes Strategic Value Div R6
CAPFX8.57N/A
N/A
Federated Hermes Capital Income F
IEMGX9.63N/A
N/A
Voya Multi-Manager Emerging Markets Eq I
STRNX52.79N/A
N/A
Sterling Capital MdCp Relatv Val C

DNTH and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with IMVT. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
-7.22%
IMVT - DNTH
42%
Loosely correlated
-11.06%
IMNM - DNTH
41%
Loosely correlated
-6.98%
PRME - DNTH
40%
Loosely correlated
-10.30%
SYRE - DNTH
40%
Loosely correlated
-5.21%
LRMR - DNTH
39%
Loosely correlated
-6.98%
More